CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,122,000 shares of the Company’s common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.37 per share, in exchange for new warrants as described below.

马萨诸塞州剑桥市。-（商业新闻短讯）--Enveric Biosciences（纳斯达克：ENVB）（“Enveric”或“公司”），一家生物技术公司，致力于开发用于治疗抑郁症，焦虑症和成瘾症的新型神经塑性小分子治疗剂，今天宣布，它已与现有认股权证的某些持有人达成协议，这些认股权证可行使1122000股公司普通股，以每股1.37美元的行使价格行使认股权证，以换取下文所述的新认股权证。

The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1.8 million, before deducting financial advisory fees. The reduction of the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules..

在扣除财务咨询费之前，现有认股权证行权的总收益预计约为180万美元。现有认股权证行权价格的降低和新认股权证的发行是根据纳斯达克规则进行的市场交易。。

Roth Capital Partners is acting as the Company’s financial advisor for this transaction.

罗斯资本合伙人（Roth Capital Partners）担任该公司此次交易的财务顾问。

The shares of common stock issuable upon exercise of the warrants are registered pursuant to a registration statement on Form S-3 (File No. 333-257690) which was declared effective by the Securities and Exchange Commission (SEC) on July 9, 2021 and a registration statement on Form S-3 (File No. 333-266579) which was declared effective by the SEC on August 11, 2022..

行使认股权证后可发行的普通股股份根据证券交易委员会（SEC）于2021年7月9日宣布生效的S-3表格登记声明（文件号333-257690）和SEC于2022年8月11日宣布生效的S-3表格登记声明（文件号333-266579）进行登记。。

In consideration for the immediate exercise of the warrants for cash and the payment of $0.125 per share underlying the new warrants, the exercising holders will receive new warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act').

考虑到立即行使现金认股权证并支付新认股权证的每股0.125美元，行权持有人将收到新认股权证，以根据修订后的《1933年证券法》（“证券法”）第4（a）（2）节的规定，以私募方式购买普通股。

The new warrants will be exercisable into an aggregate of up to 2,244,000 shares of common stock, at an exercise price of $1.37 per share and have a term of exercise equal to five years. The securities offered in the private placement have not been registered under the Securities Act, or applicable under state securities laws.

新的认股权证将可行权至2244000股普通股，行权价格为每股1.37美元，行权期限为五年。私募发行的证券未根据《证券法》注册，也未根据州证券法适用。

Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 10 days of the closing to register the resale of the shares of common stock underlying the new warrants issued in the private placement..

因此，除非根据有效的登记声明或《证券法》和此类适用的州证券法登记要求的适用豁免，否则不得在美国发售或出售证券。作为交易的一部分，公司同意在交割后10天内向美国证券交易委员会提交表S-3中的转售登记声明，以登记私募发行的新权证所属普通股的转售情况。。

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction..

本新闻稿不构成出售或招揽购买这些证券的要约，也不构成在根据任何该等司法管辖区的证券法注册或取得资格之前，在任何司法管辖区内出售这些证券是非法的。。

About Enveric Biosciences

关于Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications.

Enveric Biosciences（纳斯达克：ENVB）是一家生物技术公司，致力于开发用于治疗抑郁症，焦虑症和成瘾症的新型神经可塑性小分子疗法。利用其独特的发现和开发平台Psybrary™, Enveric为特定的心理健康适应症创建了一个强大的新化学实体知识产权组合。

Enveric’s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.

Enveric的主要计划EVM201系列包括活性代谢物psilocin的下一代合成前药。Enveric正在开发EVM201系列的第一款产品EB-373，用于治疗精神疾病。Enveric还正在推进其第二个项目EVM301系列，预计将为治疗难以解决的心理健康障碍提供一流的新方法，该方法通过促进神经可塑性而不会引起患者的幻觉。

Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com..

Enveric总部位于佛罗里达州那不勒斯，在马萨诸塞州剑桥和加拿大卡尔加里设有办事处。有关更多信息，请访问www.enveric.com。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information.

本新闻稿包含适用证券法含义内的前瞻性声明和前瞻性信息。这些陈述与未来事件或未来表现有关。除历史事实陈述外的所有陈述都可能是前瞻性陈述或信息。

Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved.

一般来说，前瞻性陈述和信息可以通过使用前瞻性术语来识别，例如“计划”、“预期”或“不预期”、“提议”、“预期”、“预算”、“计划”、“估计”、“预测”、“打算”、“预期”或“不预期”或“相信”，或这些单词和短语的变体，或者通过使用词语或短语来说明某些行动、事件或结果可能、可能、将会或可能发生或实现。

Forward-looking statements may include historical statements and statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: carry out successful clinical programs in Australia; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of .

前瞻性陈述可能包括历史陈述和关于未来信念、计划、期望或意图的陈述，并基于管理层的信念以及管理层做出的假设和目前可获得的信息。由于某些因素，实际结果可能与前瞻性声明所预期的结果存在重大差异，包括但不限于Enveric在澳大利亚开展成功临床项目的能力；实现技术开发所预期的价值创造；避免延误计划的临床试验；确定潜在产品在临床前或临床试验中有效或安全；建立或维持合作，以开发治疗候选人；获得适当或必要的政府批准，以营销潜在产品；以合理的商业条款获得未来产品开发资金和营运资金；扩大制造。

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law..

Enveric向证券交易委员会提交的文件中阐述了对这些因素和其他因素的讨论，包括与Enveric相关的风险和不确定性，包括Enveric在表格10-K中的年度报告和在表格10-Q中的季度报告。Enveric不承担任何修改任何前瞻性声明的意图或义务，无论是由于新信息、未来事件还是其他原因，除非法律要求。。